Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gumetinib plus nab-docetaxel versus docetaxel in MET-overexpressing advanced non-small cell lung cancer
CTR20242289Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gumetinib, docetaxel, albumin-bound docetaxel in non-small cell lung cancer (NSCLC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2024; status: active.
02
Drugs
gumetinibdocetaxelalbumin-bound docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242289.